Early inflammatory arthritis 2024 report (NEIAA)
The National Early Inflammatory Arthritis Audit (NEIAA) has published a State of the Nation Summary Report 2024. Based on data collected between 1 April 2023 and 31 March 2024 in England and Wales, it states that engagement with the project is more widespread than ever, with all eligible units returning some data since the last report, an increase from 96.4% to 100%.
Other key messages include:
- Improved treatment timeliness – the proportion of eligible patients starting disease-modifying antirheumatic drug (DMARD) therapy within six weeks of referral was 8% higher than reported in year five
- Remission rates within 12 weeks of treatment remain stable at 35%, however, geographic variation persists
- There is a significant burden of EIA symptoms on patients’ quality of life and employment
- There has been an increase in patient-reported mental health symptoms, continuing a trend over the last six years
- Waiting times for rare autoimmune rheumatic disease (RAIRD) diagnoses are highly variable.
The report also contains five recommendations which aim to enhance the quality of care for people living with EIA, reduce variation in care provision and outcomes, and ensure compliance with quality standards.
Read the full report: You can read the report by clicking on the link below.
Stay up-to-date: For notifications of future reports from HQIP, sign up to our mailing list.
